Literature DB >> 11153663

Increased levels of activated subsets of CD4 T cells add to the prognostic value of low CD4 T cell counts in a cohort of HIV-infected drug users.

J Carbone1, J Gil, J M Benito, J Navarro, A Muñóz-Fernández, J Bartolomé, J M Zabay, F López, E Fernández-Cruz.   

Abstract

OBJECTIVE: To identify subsets of CD4 T lymphocytes that can predict the development of AIDS and to assess whether increased levels of these cellular markers could provide additional independent prognostic information to the CD4 T cell count and plasma HIV-1-RNA levels. DESIGN AND METHODS: In a prospective study, a cohort of 85 HIV-positive intravenous drug users [clinical categories of the CDC classification A (n = 48) and B (n = 37)] were followed for a period of 37+/-13 months. Memory and activated CD4 and CD8 T cells were quantitated by three-colour flow cytometry at baseline and expressed as a percentage of total CD4 and CD8 lymphocytes. Clinical evaluations were performed at 6 month intervals. The relationships between these lymphocyte subsets and progression to AIDS were studied using Kaplan-Meier plots and proportional hazards regression models.
RESULTS: After adjustment for the level of CD4 T cells and plasma HIV-1-RNA levels, the elevation in the subset CD4+CD38+DR+ was the marker within the functionally distinct subsets of CD4 T lymphocytes with additional prognostic value in bivariate Cox regression models. In multivariate models, increased percentages of CD4+CD38+DR+ T cells provided the strongest independent prognostic information for progression to AIDS (relative hazard, 1.07; P < 0.0001).
CONCLUSION: Our results suggest that high levels of CD4+CD38+HLA-DR+ T cells reflect the increasing degree of CD4 T cell activation during the progression of HIV infection, and could be used together with the CD4 T cell and HIV-RNA levels to evaluate more accurately the progressive cellular immune impairment associated with the risk of progression to AIDS.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11153663     DOI: 10.1097/00002030-200012220-00003

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  16 in total

1.  Low immune activation despite high levels of pathogenic human immunodeficiency virus type 1 results in long-term asymptomatic disease.

Authors:  Shailesh K Choudhary; Nienke Vrisekoop; Christine A Jansen; Sigrid A Otto; Hanneke Schuitemaker; Frank Miedema; David Camerini
Journal:  J Virol       Date:  2007-05-30       Impact factor: 5.103

2.  Limited CD4+ T cell proliferation leads to preservation of CD4+ T cell counts in SIV-infected sooty mangabeys.

Authors:  Ming Liang Chan; Janka Petravic; Alexandra M Ortiz; Jessica Engram; Mirko Paiardini; Deborah Cromer; Guido Silvestri; Miles P Davenport
Journal:  Proc Biol Sci       Date:  2010-06-30       Impact factor: 5.349

Review 3.  CD4+ T-cell depletion in HIV infection: killed by friendly fire?

Authors:  Abeer Moanna; Richard Dunham; Mirko Paiardini; Guido Silvestri
Journal:  Curr HIV/AIDS Rep       Date:  2005-02       Impact factor: 5.071

4.  Short communication: Apoptosis pathways in HIV-1-infected patients before and after highly active antiretroviral therapy: relevance to immune recovery.

Authors:  David L Pitrak; Richard M Novak; Randee Estes; Jean Tschampa; Christina D Abaya; Jeffrey Martinson; Kirsten Bradley; Allan R Tenorio; Alan L Landay
Journal:  AIDS Res Hum Retroviruses       Date:  2014-11-11       Impact factor: 2.205

5.  Effects of antiretroviral therapy on immune function of HIV-infected adults with pulmonary tuberculosis and CD4+ >350 cells/mm3.

Authors:  Christina L Lancioni; C Scott Mahan; Denise F Johnson; Maria Walusimbi; Keith A Chervenak; Sophie Nalukwago; Edwin Charlebois; Diane Havlir; Harriet Mayanja-Kizza; Christopher C Whalen; W Henry Boom
Journal:  J Infect Dis       Date:  2011-04-01       Impact factor: 5.226

6.  HIV-specific CD4+ T cells may contribute to viral persistence in HIV controllers.

Authors:  Peter W Hunt; Hiroyu Hatano; Elizabeth Sinclair; Tzong-Hae Lee; Michael P Busch; Jeffrey N Martin; Joseph M McCune; Steven G Deeks
Journal:  Clin Infect Dis       Date:  2011-01-18       Impact factor: 9.079

7.  Immune activation markers in individuals with HIV-1 disease and their correlation with HIV-1 RNA levels in individuals on antiretroviral therapy.

Authors:  Jyoti Sangwan; Sourav Sen; Rajiv Mohan Gupta; K Shanmuganandan; Rajan S Grewal
Journal:  Med J Armed Forces India       Date:  2019-10-15

8.  Abnormal activation and cytokine spectra in lymph nodes of people chronically infected with HIV-1.

Authors:  Angélique Biancotto; Jean-Charles Grivel; Sarah J Iglehart; Christophe Vanpouille; Andrea Lisco; Scott F Sieg; Robert Debernardo; Kristen Garate; Benigno Rodriguez; Leonid B Margolis; Michael M Lederman
Journal:  Blood       Date:  2007-02-08       Impact factor: 22.113

9.  Correlates of immune activation marker changes in human immunodeficiency virus (HIV)-seropositive and high-risk HIV-seronegative women who use illicit drugs.

Authors:  Alan Landay; Lorie Benning; James Bremer; Barbara Weiser; Harold Burger; Marek Nowicki; Andrea Kovacs
Journal:  J Infect Dis       Date:  2003-07-01       Impact factor: 5.226

10.  Replication capacity in relation to immunologic and virologic outcomes in HIV-1-infected treatment-naive subjects.

Authors:  Gail Skowron; John G Spritzler; Jodi Weidler; Gregory K Robbins; Victoria A Johnson; Ellen S Chan; David M Asmuth; Rajesh T Gandhi; Yolanda Lie; Michael Bates; Richard B Pollard
Journal:  J Acquir Immune Defic Syndr       Date:  2009-03-01       Impact factor: 3.731

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.